Serveur d'exploration COVID et hydrochloroquine - Exploration (Accueil)

Index « MeshFr.i » - entrée « Pyrazines »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Pustulose exanthématique aigüe généralisée < Pyrazines < Pyrazoles  Facettes :

List of bibliographic references indexed by Pyrazines

Number of relevant bibliographic references: 50.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000020 (2021) Fabio Cruciani [Italie] ; Laura Amato [Italie] ; Franco De Crescenzo ; Zuzana Mitrova [Italie] ; Rosella Saulle [Italie] ; Simona Vecchi [Italie] ; Marina Davoli [Italie][The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.]
000104 (2021) Farah Daou [Liban] ; Gretta Abou-Sleymane [Liban] ; Danielle A. Badro [Liban] ; Nagham Khanafer [France] ; Mansour Tobaiqy [Arabie saoudite] ; Achraf Al Faraj [Liban]The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19.
000138 (2021) Katharina Habler [Allemagne] ; Mathias Brügel [Allemagne] ; Daniel Teupser [Allemagne] ; Uwe Liebchen [Allemagne] ; Christina Scharf [Allemagne] ; Ulf Schönermarck [Allemagne] ; Michael Vogeser [Allemagne] ; Michael Paal [Allemagne]Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum.
000158 (2021) Hany M. Dabbous [Égypte] ; Manal H. El-Sayed [Égypte] ; Gihan El Assal [Égypte] ; Hesham Elghazaly [Égypte] ; Fatma F S. Ebeid [Égypte] ; Ahmed F. Sherief [Égypte] ; Maha Elgaafary [Égypte] ; Ehab Fawzy [Égypte] ; Sahar M. Hassany [Égypte] ; Ahmed R. Riad [Égypte] ; Mohamed A. Tageldin [Égypte]Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial.
000230 (2021) Faryal Khamis [Oman] ; Hanan Al Naabi [Oman] ; Adil Al Lawati [Oman] ; Zaiyana Ambusaidi [Oman] ; Mariam Al Sharji [Oman] ; Umkulthum Al Barwani [Oman] ; Nenad Pandak [Oman] ; Zakariya Al Balushi [Oman] ; Maher Al Bahrani [Oman] ; Issa Al Salmi [Oman] ; Ibrahim Al-Zakwani [Oman]Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia.
000290 (2021) Nursel Çal K Ba Aran [Turquie] ; O Uz Abdullah Uyaro Lu [Turquie] ; Gülçin Telli Dizman [Turquie] ; Lale Öz K [Turquie] ; Taha Koray Ahin [Turquie] ; Zahit Ta [Turquie] ; Ahmet Ça Kan Nkaya [Turquie] ; Sevilay Karahan [Turquie] ; Ehnaz Alp [Turquie] ; Alpaslan Alp [Turquie] ; Gökhan Metan [Turquie] ; P Nar Zarakol [Turquie] ; Gülay Sain Güven [Turquie] ; Erife Gül Öz [Turquie] ; Arzu Topeli [Turquie] ; Ömrüm Uzun [Turquie] ; Murat Akova [Turquie] ; Serhat Ünal [Turquie]Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU
000294 (2021) Sanjay Kumar Mishra [Inde] ; Timir Tripathi [Inde]One year update on the COVID-19 pandemic: Where are we now?
000297 (2021) Havva Kocayi It [Turquie] ; Kezban Özmen Süner [Turquie] ; Yakup Tomak [Turquie] ; Gürkan Demir [Turquie] ; Selçuk Yaylac [Turquie] ; Hamad Dheir [Turquie] ; Ertu Rul Güçlü [Turquie] ; Ali Fuat Erdem [Turquie]Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
000338 (2021) Florence Rodgers [Royaume-Uni] ; Toby Pepperrell [Royaume-Uni] ; Sarai Keestra [Pays-Bas, Royaume-Uni] ; Victoria Pilkington [Royaume-Uni]Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs.
000504 (2021) Nurullah Okumu [Turquie] ; Ne E Demirtürk [Turquie] ; R Za Aytaç Çetinkaya [Turquie] ; Rahmet Güner [Turquie] ; Smail Ya Ar Avc [Turquie] ; Semiha Orhan [Turquie] ; Petek Konya [Turquie] ; Bengü Aylan [Turquie] ; Ay Egül Karalezli [Turquie] ; Levent Yamanel [Turquie] ; Bircan Kayaaslan [Turquie] ; Gülden Y Lmaz [Turquie] ; Ümit Sava Ç [Turquie] ; Fatma Eser [Turquie] ; Gürhan Ta K N [Turquie]Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients.
000511 (2021) Rujipas Sirijatuphat [Thaïlande] ; Yupin Suputtamongkol [Thaïlande] ; Nasikarn Angkasekwinai [Thaïlande] ; Navin Horthongkham [Thaïlande] ; Methee Chayakulkeeree [Thaïlande] ; Pinyo Rattanaumpawan [Thaïlande] ; Pornpan Koomanachai [Thaïlande] ; Susan Assanasen [Thaïlande] ; Yong Rongrungruang [Thaïlande] ; Nitipatana Chierakul [Thaïlande] ; Ranistha Ratanarat [Thaïlande] ; Anupop Jitmuang [Thaïlande] ; Walaiporn Wangchinda [Thaïlande] ; Wannee Kantakamalakul [Thaïlande]Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand's university-based referral hospital.
000514 (2021) Maria Gavriatopoulou [Grèce] ; Ioannis Ntanasis-Stathopoulos [Grèce] ; Eleni Korompoki [Grèce, Royaume-Uni] ; Despina Fotiou [Grèce] ; Magdalini Migkou [Grèce] ; Ioannis-Georgios Tzanninis [Royaume-Uni] ; Theodora Psaltopoulou [Grèce] ; Efstathios Kastritis [Grèce] ; Evangelos Terpos [Grèce] ; Meletios A. Dimopoulos [Grèce]Emerging treatment strategies for COVID-19 infection.
000594 (2021) Rahmet Guner [Turquie] ; Imran Hasanoglu [Turquie] ; Bircan Kayaaslan [Turquie] ; Adalet Aypak [Turquie] ; Esragul Akinci [Turquie] ; Hurrem Bodur [Turquie] ; Fatma Eser [Turquie] ; Ayse Kaya Kalem [Turquie] ; Orhan Kucuksahin [Turquie] ; Ihsan Ates [Turquie] ; Aliye Bastug [Turquie] ; Yasemin Tezer Tekce [Turquie] ; Zeynep Bilgic [Turquie] ; Fahriye Melis Gursoy [Turquie] ; Hatice Nisa Akca [Turquie] ; Seval Izdes [Turquie] ; Deniz Erdem [Turquie] ; Emra Asfuroglu [Turquie] ; Habibe Hezer [Turquie] ; Hatice Kilic [Turquie] ; Musa C Vak [Turquie] ; Sibel Aydogan [Turquie] ; Turan Buzgan [Turquie]Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.
000650 (2021) Burcu Ceylan Cura Yayla [Turquie] ; Kubra Aykac [Turquie] ; Yasemin Ozsurekci [Turquie] ; Mehmet Ceyhan [Turquie]Characteristics and Management of Children With COVID-19 in a Tertiary Care Hospital in Turkey.
000729 (2021) Ambedkar Kumar Yadav [République populaire de Chine] ; Siwan Wen [République populaire de Chine] ; Xianghuai Xu [République populaire de Chine] ; Li Yu [République populaire de Chine]Antiviral treatment in COVID-19: which is the most promising?-a narrative review.
000773 (2021) Dorna Kheirabadi [Iran] ; Fatemeh Haddad [Iran] ; Razieh S. Mousavi-Roknabadi [Iran] ; Mohammad Rezaeisadrabadi [Iran] ; Hamidreza Dehghan [Iran] ; Aylar Fazlzadeh [Iran]A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic.
000777 (2021) Theerachai Thammathiwat [Thaïlande] ; Somkanya Tungsanga [Thaïlande] ; Kanitha Tiankanon [Thaïlande] ; Pattama Torvorapanit [Thaïlande] ; Worawat Chumpangern [Thaïlande] ; Suwasin Udomkarnjananun [Thaïlande] ; Yingyos Avihingsanon [Thaïlande] ; Thitiwat Sriprasart [Thaïlande] ; Nattachai Srisawat [Thaïlande] ; Kamonwan Jutivorakool [Thaïlande] ; Leilani Paitoonpong [Thaïlande] ; Opass Putcharoen [Thaïlande] ; Natavudh Townamchai [Thaïlande]A case of successful treatment of severe COVID-19 pneumonia with favipiravir and tocilizumab in post-kidney transplant recipient.
000807 (2020) Melanie Bilbul [États-Unis] ; Patricia Paparone [États-Unis] ; Anna M. Kim [États-Unis] ; Shruti Mutalik [États-Unis] ; Carrie L. Ernst [États-Unis]Psychopharmacology of COVID-19.
000832 (2020) Murat Çap [Turquie] ; Önder Bilge [Turquie] ; Ferhat I K [Turquie] ; Cengiz Burak [Turquie] ; Ali Karagöz [Turquie] ; Ümit Nci [Turquie] ; Abdurrahman Akyüz [Turquie] ; Burhan Aslan [Turquie] ; Bernas Alt Nta [Turquie] ; Rojhat Alt Nda [Turquie] ; Lyas Kaya [Turquie] ; Mehmet Ahin Ad Yaman [Turquie] ; Muhammed Süleymano Lu [Turquie] ; Afak Kaya [Turquie] ; Erkan Baysal [Turquie]The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019.
000867 (2020) Saleh A. Alqahtani [Arabie saoudite, États-Unis] ; Abdulrahman A. Aljumah [Arabie saoudite] ; Almoutaz Hashim [Arabie saoudite] ; Thamer H. Alenazi [Arabie saoudite] ; Mohammed Aljawad ; Waleed K. Al Hamoudi [Arabie saoudite] ; Mohammed Y. Alghamdi [Arabie saoudite]Principles of Care for Patients with Liver Disease During the Coronavirus Disease 2019 (COVID-19) Pandemic: Position Statement of the Saudi Association for the Study of Liver Disease and Transplantation.
000947 (2020) Lenka Petroušová [République tchèque] ; Simona Da Silva ; Lud K Rožnovsk ; Irena Martinková[Clinical progression of the first wave of novel coronavirus infection in Ostrava].

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/MeshFr.i -k "Pyrazines" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/MeshFr.i  \
                -Sk "Pyrazines" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    MeshFr.i
   |clé=    Pyrazines
}}

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021